Workflow
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC ImmuneAC Immune(US:ACIU) Globenewswireยท2025-08-05 11:00

Core Viewpoint - AC Immune SA is advancing its pipeline of precision therapeutics for neurodegenerative diseases, with significant progress in multiple clinical programs and a strong financial position to support ongoing development [2][3][4]. Financial Results - For Q2 2025, AC Immune reported contract revenues of CHF 1.3 million, an increase from CHF 0.7 million in the same period of 2024 [12]. - The company recorded a net loss of CHF 21.2 million for Q2 2025, compared to a net loss of CHF 22.8 million in Q2 2024 [12][20]. - Research and development expenses decreased to CHF 16.8 million from CHF 17.1 million year-over-year, while general and administrative expenses also saw a decline to CHF 3.9 million from CHF 4.6 million [12][20]. Pipeline Development - AC Immune has three active immunotherapies in Phase 2 clinical development, including ACI-7104.056, which has shown strong immunogenicity and a favorable safety profile in early Parkinson's disease [3][7]. - The ACI-24.060 program is expected to reach a 12-month treatment milestone in December 2025, with interim results anticipated in early 2026 [7][9]. - The company is also advancing its small molecule NLRP3 program, ACI-19764, which is currently in IND-enabling studies [7][9]. Cash Position - As of June 30, 2025, AC Immune had a cash balance of CHF 127.1 million (approximately USD 157.6 million), providing funding into Q1 2027, excluding potential milestone payments [4][12]. Upcoming Milestones - Interim results from the VacSYn trial of ACI-7104.056 are expected later in 2025, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment by year-end 2025 [4][7]. - The company plans to file an IND for ACI-19764 within the year [4][9].